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Abstract
Introduction: Many women who survive breast cancer die of causes unrelated to their cancer diagnosis. This study
was undertaken to assess factors that are related to breast cancer mortality versus mortality from other causes and
to describe the leading causes of death among older women diagnosed with breast cancer.
Methods: Women diagnosed with breast cancer at age 66 or older between 1992 and 2000 were identified in the
Surveillance, Epidemiology and End Results-Medicare linked database and followed through the end of 2005.
Results: A total of 63,566 women diagnosed with breast cancer met the inclusion criteria and were followed for a
median of approximately nine years. Almost one-half (48.7%) were alive at the end of follow-up. Ages and
comorbidities at the time of diagnosis had the largest effects on mortality from other causes, while tumor stage,
tumor grade, estrogen receptor status, age and comorbidities at the time of diagnosis all had effects on breast
cancer-specific mortality. Fully adjusted relative hazards of the effects of comorbidities on breast cancer-specific
mortality were 1.24 (95% confidence interval (95% CI) 1.13 to 1.26) for cardiovascular disease, 1.13 (95% CI 1.13 to
1.26) for previous cancer, 1.13 (95% CI 1.05 to 1.22) for chronic obstructive pulmonary disease and 1.10 (95% CI
1.03 to 1.16) for diabetes. Among the total study population, cardiovascular disease was the primary cause of death
in the study population (15.9% (95% CI 15.6 to 16.2)), followed closely by breast cancer (15.1% (95% CI 14.8 to
15.4)).
Conclusions: Comorbid conditions contribute importantly to both total mortality and breast cancer-specific
mortality among breast cancer survivors. Attention to reducing the risk of cardiovascular disease should be a
priority for the long-term care of women following the diagnosis and treatment of breast cancer.
Introduction
Mortality rates for breast cancer have declined since
1990. In 2006, there were about 2.5 million women in
the United States who had survived breast cancer (diag-
nosed at any point prior to 1 January 2006) [1]. The sur-
vivorship of breast cancer patients depends on many
factors, including age at diagnosis, tumor stage, tumor
grade, estrogen receptor (ER) status, progesterone recep-
tor status, socioeconomic factors and other non-cancer-
related clinical conditions such as preexisting health sta-
tus, functional status and social connections [2-4].
Research has shown that other preexisting chronic con-
ditions, or comorbidities, also have a significant effect
on the overall survival of breast cancer patients [5-7].
The current study assesses the effects of comorbidities
on outcomes of breast cancer mortality and mortality
from other causes among breast cancer survivors ages
66 and older.
T h em o s tc o m m o n l yu s e do u t c o m ew h e nc o n d u c t i n g
epidemiologic research on cancer survivorship is all-
cause mortality, which, among individuals with breast
cancer, is the sum of breast cancer-specific mortality
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single cause of death is difficult and can be somewhat
arbitrary, assessing outcomes for both breast cancer-spe-
cific mortality and mortality from other causes can assist
healthcare providers and patients with breast cancer in
assessing prognostic indicators and other decisions
made in primary care. This study describes the effect of
select characteristics, including comorbid conditions, on
breast cancer-specific mortality compared to mortality
from other causes and explores leading causes of death
among breast cancer survivors.
Materials and methods
Data source
The Surveillance, Epidemiology and End Results (SEER)-
Medicare linked database was utilized for this analysis.
This database is a linkage of records from SEER, a large
cancer registry, and Medicare, the national healthcare
system for older persons. The SEER registry is designed
to track primary cancer incidence and survival in the
United States. Although not all US states report cancer
cases to the SEER program, it is designed to be repre-
sentative of data from the whole country. SEER partici-
pation has expanded greatly since its inception. While
initially capturing approximately 10% of the US popula-
tion in 1973, the SEER program has grown to comprise
26% of the US population currently [8]. The population
covered by SEER is comparable to the general US popu-
lation with regard to measures of poverty and education.
However, the SEER registry population represents a
somewhat more urban population and has a higher pro-
portion of foreign-born persons than are found in the
general US population. The compilers of the SEER regis-
try continually monitor and evaluate their data to ensure
high quality. The program’s standard for registry com-
pleteness for the incidence of cancer cases is 98% [9].
The SEER registry collects information on gender, race,
and dates of birth and death, cause of death, as well as
tumor-specific information such as diagnosis date,
tumor stage at diagnosis, tumor grade, ER and proges-
terone receptor status, and surgery and/or radiation
treatments within four months after cancer diagnosis.
Medicare is a US system of federally funded health
insurance for persons ages 65 years and older. Medicare
part A covers hospital, skilled-nursing facility, hospice
and some home health care services. Medicare part B
covers physician and outpatient services. Virtually all
beneficiaries receive part A, and 96% of beneficiaries
choose to pay a monthly premium for part B. Medicare
patients can be enrolled in either a fee-for-service (FFS)
or health maintenance organization (HMO) plan. Claims
files are not available for the 17% of Medicare recipients
who are in an HMO plan [9]. Medicare data include
demographic information and surgical and radiation
treatment information that are already in the SEER data-
base, as well as information on comorbid conditions and
chemotherapy treatment. The SEER database has a
unique code that does not include identifying informa-
tion; therefore, the research that we conducted was
exempt from institutional review board approval by the
Colorado Multiple Institutional Review Board.
Study population
Women diagnosed with primary cancers of the breast at
age 66 years or older and entered into the SEER data
set from 1 January 1992 through 31 December 2000
were eligible for inclusion into our study. Women ages
65 years old were not included to allow for a one-year
time period following Medicare enrollment during
which comorbidities could be recorded in claims files.
Women were excluded if they (1) lacked full insurance
coverage under both Medicare part A and part B, (2)
were enrolled in a Medicare HMO, (3) had an unknown
month of cancer diagnosis, (4) had the same month of
diagnosis and death, (5) had an unknown cause of
death, and/or (6) had records considered to have unreli-
able Medicare coding for a comorbid condition (most
commonly bills that were not encoded by a clinician for
a specific reason for the visit). These exclusion criteria
ensured that claims files were available for accurate
detection of comorbidities and calculation of survival
times from diagnosis to death.
A total of 96,954 women ages 66 years and older diag-
nosed with malignant breast cancer between 1992 and
2000 were potentially eligible for inclusion in this study.
Just over one-third (33,388, or 34.4%) were excluded for
the following reasons: being in a Medicare HMO
(22.8%), unreliable diagnosis coding (4.0%), not having
both Medicare parts A and B insurance coverage (5.5%),
month and year of death the same as the diagnosis
(2.6%), unknown month of diagnosis (0.7%) and/or
unknown cause of death (0.5%).
Measurement of treatment and comorbidities
Medicare files were searched for diagnostic and proce-
dural codes related to the comorbidities and treatments
of interest [10]. Codes for diagnoses and procedures
were derived from the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM) [11], the Health Care Financing Administration
Common Procedure Coding System and revenue center
codes [12]. Medicare files for claims from inpatient, out-
patient and physician visits were utilized.
In addition to SEER fields of surgery and radiation
treatment within four months after breast cancer diag-
nosis, Medicare files were searched for chemotherapy
and radiation codes. Patients with at least one che-
motherapy code within six months after cancer
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apy code within nine months after cancer diagnosis
were categorized as receiving those respective therapies.
Data on hormonal therapy are not available in the
SEER-Medicare database and therefore were not
included in our analysis. Specific codes used to identify
chemotherapy and radiation treatment are listed in
Additional file 1.
Comorbidities included in this study are those 19 con-
ditions that were found to affect survival by Charlson et
al. [13,14] and adapted by Deyo et al. [15] and Klabunde
et al. [16] to be used with administrative claims data.
Rather than using the combined Charlson Comorbidity
Index, the current study assesses the individual effects
of each of the comorbidities included in the Charlson
Index. The Medicare files were searched for comorbidity
diagnoses appearing during the time periods one year
before and 30 days after the cancer diagnosis. This
longer period before cancer diagnosis and the short per-
iod after cancer diagnosis allows for substantial time to
identify diagnoses representing comorbidities without
capturing conditions that may result from the cancer
treatment. Diagnostic coding for comorbidities was
made only if the comorbidity condition was included in
Medicare inpatient files or if the condition had been
coded at least twice at least 30 days apart in either the
outpatient or physician files. The comorbid condition of
previous cancer was determined from the SEER
database.
For this analysis, we combined Charlson categories
that were separated by severity (for example, diabetes
and diabetes with complications) and further grouped
conditions of myocardial infarction, congestive heart
failure, peripheral vascular disease and cerebrovascular
disease into one category of cardiovascular disease
(CVD). Women without any of the 19 conditions com-
prised the group “No comorbidities.” Only the four
most common comorbid conditions within the Charlson
index, previous cancer, CVD, chronic obstructive pul-
monary disease (COPD) and diabetes, are included in
the current study.
Underlying cause of death
The SEER registry uses US state death certificates to
obtain information on the underlying cause of death
encoded with the ICD-9 diagnostic codes. The underly-
ing cause of death according to the ICD-9 diagnostic
codes is defined as “the disease or injury that initiated
the train of morbid events leading directly to death or
the circumstances of the accident or violence that pro-
duced the injury” [17]. In the current study, deaths were
attributed to either breast cancer or other causes.
Deaths due to cancers other than breast cancer are
included in the other-cause mortality group.
Statistical analysis
The study population was categorized into three study
groups: (1) women who were alive at the end of the
study period, (2) women who died as a result of breast
cancer-specific reasons during the study period and (3)
women who died as a result of other causes. For ana-
lyses involving breast cancer-specific mortality, deaths
from other causes were censored at time of death and
vice versa. Since the SEER registry does not include the
specific diagnosis date or the specific death date, the
15th of the month was arbitrarily assigned to the
reported month and year. The study population was fol-
lowed through the end of 2005.
Descriptive statistics of the three study groups are
presented. Cox proportional hazards models were used
to calculate relative hazards of breast cancer mortality
and other-cause mortality for population characteris-
tics adjusted for age and fully adjusted for age and
other characteristics. Causes of death were grouped
into the three leading causes: breast cancer, other can-
cer and CVD. All other causes of death were grouped
into the category “Other.” Proportional distributions of
cumulative causes of death were explored according to
a g eg r o u p( 6 6t o7 4y e a r s ,7 5t o8 4y e a r sa n d8 5y e a r s
and older) and cancer stage (stage I, stage II and stages
III and IV), as well as by duration of follow-up. Miss-
ing or unknown data were grouped into their own
categories and were included in Cox proportional
hazards models. Two approaches were used to assess
whether missing predictors had an influence on the
main findings: (1) records with missing or unknown
values for any variables of interest were excluded from
the analyses, and (2) the R package NestedCohort [18]
was used to weight records with known values regard-
ing age, race/ethnicity and death status to account for
records with missing data. Accounting for missing or
unknown data did not influence the results. SAS ver-
sion 9.1 software (SAS Institute, Cary, NC, USA) was
used for analysis.
Results
A total of 63,566 women met the study inclusion cri-
teria. Among these women, 32,594 individuals (51.3%)
died during the study period: 15.1% (95% confidence
interval (95% CI) 14.8 to 15.4) of the study population
died as a result of breast cancer and 36.2% (95% CI 35.5
to 36.3) died as a result of other causes. The median fol-
low-up time was 105 months (range 1 to 167 months),
and the median age at death was 83 years (range 66 to
110 years). Women with higher tumor stages and grades
and ER-negative status were more likely to die as a
result of breast cancer during the study period. Older
w o m e nw e r em u c hm o r el i k e l yt od i ea sar e s u l to f
other causes (Table 1).
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cancer were 16.3% for previous cancer, 13.0% for dia-
betes, 12.8% for CVD and 8.8% for COPD, and the pre-
valence estimates were higher for older women. Women
with no comorbidities were more likely than women
with comorbidities to be alive at the end of the study
period (Table 1). In the overall study population, 36.2%
of women died as a result of causes other than breast
cancer. Women with the following comorbidities were
more likely to die as a result of other causes: CVD
(59.2%), COPD (52.2%), diabetes (47.8%) and previous
cancer (43.8%).
The age-adjusted relative hazards of dying as a result
of breast cancer and other causes were greater among
women with higher tumor stages and grades, black
women, women with ER-negative status and women
Table 1 Prevalence of population characteristics by mortality status among breast cancer patients ages 66 years and
older, SEER-Medicare data from 1992 to 2000
a
Characteristics Alive Breast cancer deaths Other-cause deaths
Total, n (%) 30,972 (48.7%) 9,608 (15.1%) 22,986 (36.2%)
Age, years, n (%)
85+ 18,054 (63.0%) 4,021 (14.0%) 6,572 (22.9%)
75 to 84 11,543 (43.9%) 3,900 (14.8%) 10,824 (41.2%)
66 to 74 1,375 (15.9%) 1,687 (19.5%) 5,590 (64.6%)
Race/ethnicity, n (%)
White 27,224 (48.9%) 8,170 (14.7%) 20,329 (36.5%)
Black 1,481 (38.3%) 889 (23.0%) 1,501 (38.8%)
Hispanic 966 (50.8%) 324 (17.0%) 613 (32.2%)
Other/unknown 1,301 (62.9%) 225 (10.9%) 543 (26.2%)
Stage, n (%)
I 19,447 (59.3%) 1,735 (5.3%) 11,597 (35.4%)
II 9,001 (44.1%) 3,546 (17.4%) 7,856 (38.5%)
III and IV 911 (15.4%) 3,296 (55.6%) 1,724 (29.1%)
Unknown 1,613 (36.2%) 1,031 (23.2%) 1,809 (40.6%)
Grade, n (%)
1 6,410 (61.3%) 497 (4.8%) 3,546 (33.9%)
2 11,966 (53.0%) 2,556 (11.3%) 8,052 (35.7%)
3 and 4 7,121 (42.6%) 3,917 (23.4%) 5,694 (34.0%)
Unknown 5,475 (39.6%) 2,638 (19.1%) 5,694 (41.2%)
ER status, n (%)
Positive 21,388 (52.5%) 4,784 (11.7%) 14,568 (35.8%)
Negative 3,471 (43.8%) 2,006 (25.3%) 2,451 (30.9%)
Unknown/other 6,113 (41.0%) 2,818 (18.9%) 5,967 (40.0%)
Surgery, n (%)
Yes 30,506 (51.1%) 7,658 (12.8%) 21,553 (36.1%)
No 152 (6.4%) 1,297 (54.7%) 921 (38.9%)
Unknown 314 (21.2%) 653 (44.2%) 512 (34.6%)
Chemotherapy, n (%)
Yes 4,709 (50.0%) 2,724 (29.0%) 1,975 (21.0%)
No 26,263 (48.5%) 6,884 (12.7%) 21,011 (38.8%)
Radiation therapy, n (%)
Yes 13,350 (61.5%) 2,798 (12.9%) 5,556 (25.6%)
No 17,622 (42.1%) 6,810 (16.3%) 17,430 (41.6%)
Comorbidity, n (%)
None 21,017 (56.7%) 5,500 (14.8%) 10,544 (28.4%)
Previous cancer 4,280 (41.4%) 1,533 (14.8%) 4,534 (43.8%)
Cardiovascular disease 1,955 (24.1%) 1,353 (16.7%) 4,794 (59.2%)
COPD 1,886 (33.6%) 798 (14.2%) 2,927 (52.2%)
Diabetes 3,000 (36.4%) 1,308 (15.9%) 3,939 (47.8%)
aSEER: Surveillance, Epidemiology and End Results; ER: estrogen receptor; COPD: chronic obstructive pulmonary disease.
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After adjustment for age, tumor stage and grade, ER sta-
tus, treatments and all other comorbid conditions, the
relative hazards of dying were different for breast can-
cer-specific mortality versus other-cause mortality. Age
affected both types of mortality, but relative hazards
were much higher when other-cause mortality was the
outcome. Tumor characteristics of stage and grade as
well as ER status greatly affected breast cancer mortality,
whereas only tumor stage affected other-cause mortality,
and to a much lesser extent than that associated with
breast cancer mortality. Relative hazards for comorbid-
ities were more highly associated with other-cause mor-
tality, although all comorbid conditions also significantly
affected breast cancer mortality. Many of the changes in
the relative hazards from the age-adjusted model to the
fully adjusted model are due to adjustments for tumor
stage among breast cancer deaths and for treatment for
both breast cancer deaths and other-cause deaths.
The distribution of causes of death varied by age and
tumor stage (Figure 1). Women diagnosed with higher-
stage cancers were much more likely to die as a result of
breast cancer than from other causes. Other causes of
death were more likely among women diagnosed with
stages I and II cancers. At all ages, women diagnosed
with stage I breast cancer were more likely to die as a
result of CVD than from breast cancer. CVD was also the
leading cause of death for women diagnosed with stage II
breast cancer who were ages 85 years and older (42.2%)
and 75 to 84 years of age (32.2%). Within all cancer
stages, as women aged, there was a decrease in the pro-
portion of all deaths that were due to breast cancer.
The proportional distribution of cumulative causes of
death was dependent on follow-up time. In the first 5 to
Table 2 Age-adjusted and fully adjusted relative hazards of breast cancer mortality and other-cause mortality among
breast cancer patients ages 66 years and older, SEER-Medicare data from 1992 to 2000
a
Breast cancer deaths Other-cause deaths
Characteristics Age-adjusted model Fully adjusted model
b Age-adjusted model Fully adjusted model
b
Age, years Crude Crude
66 to 74 Reference Reference Reference Reference
75 to 84 1.21 (1.16 to 1.27) 1.20 (1.14 to 1.26) 2.28 (2.21 to 2.34) 2.04 (1.98 to 2.10)
85+ 2.23 (2.10 to 2.36) 1.67 (1.57 to 1.78) 6.08 (5.86 to 6.31) 4.63 (4.46 to 4.82)
Race/ethnicity
White Reference Reference Reference Reference
Black 1.79 (1.67 to 1.92) 1.12 (1.05 to 1.21) 1.29 (1.23 to 1.36) 1.05 (0.99 to 1.10)
Hispanic 1.21 (1.08 to 1.35) 0.96 (0.86 to 1.08) 0.97 (0.89 to 1.05) 0.87 (0.81 to 0.95)
Other/unknown 0.73 (0.64 to 0.83) 0.76 (0.66 to 0.87) 0.75 (0.68 to 0.81) 0.73 (0.67 to 0.80)
Stage
I Reference Reference Reference Reference
II 3.72 (3.51 to 3.94) 3.05 (2.88 to 3.24) 1.26 (1.23 to 1.30) 1.24 (1.20 to 1.27)
III and IV 19.9 (18.8 to 21.1) 11.50 (10.8 to 12.3) 1.76 (1.67 to 1.85) 1.65 (1.56 to 1.74)
Unknown 5.38 (4.98 to 5.81) 2.88 (2.64 to 3.13) 1.37 (1.30 to 1.44) 1.03 (0.97 to 1.09)
Grade
1 Reference Reference Reference Reference
2 2.45 (2.22 to 2.70) 1.76 (1.60 to 1.94) 1.07 (1.03 to 1.11) 1.04 (1.00 to 1.08)
3 and 4 5.64 (5.14 to 6.20) 2.63 (2.39 to 2.90) 1.18 (1.13 to 1.23) 1.09 (1.05 to 1.14)
Unknown 4.34 (3.94 to 4.78) 1.93 (1.75 to 2.13) 1.21 (1.16 to 1.27) 1.06 (1.01 to 1.11)
ER status
Positive Reference Reference Reference Reference
Negative 2.48 (2.35 to 2.61) 1.71 (1.62 to 1.81) 1.05 (1.01 to 1.10) 1.03 (0.99 to 1.08)
Unknown/other 1.78 (1.70 to 1.87) 1.24 (1.18 to 1.31) 1.22 (1.18 to 1.26) 1.08 (1.05 to 1.12)
Comorbidity
None Reference Reference Reference Reference
Previous cancer 1.10 (1.03 to 1.16) 1.20 (1.13 to 1.26) 1.68 (1.63 to 1.74) 1.29 (1.25 to 1.34)
Cardiovascular disease 1.44 (1.36 to 1.53) 1.24 (1.17 to 1.32) 2.83 (2.73 to 2.94) 1.87 (1.80 to 1.93)
COPD 1.20 (1.12 to 1.30) 1.13 (1.05 to 1.22) 2.66 (2.56 to 2.78) 1.71 (1.65 to 1.78)
Diabetes 1.31 (1.24 to 1.40) 1.10 (1.03 to 1.16) 2.37 (2.28 to 2.46) 1.57 (1.52 to 1.63)
aSEER: Surveillance, Epidemiology and End Results; ER: estrogen receptor; COPD: chronic obstructive pulmonary disease.
bAdjusted for age, race/ethnicity, stage,
grade, ER status, surgery, radiation, chemotherapy and all comorbidities. Data are expresses as relative hazards (95% confidence intervals).
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was the cumulative primary cause of death. With longer
follow-up, CVD became the cumulative primary cause
of death (Figure 2). The proportion of deaths due to
other causes also increased as follow-up increased. The
primary causes of death in this category included deaths
due to COPD (3.8% of all deaths), pneumonia (2.8%),
Alzheimer’s disease (2.2%) and diabetes (2.2%).
Discussion
Older female Medicare enrollees were more than twice
as likely to die as a result of diseases other than breast
cancer (36.2% versus 15.1%). Characteristics associated
with dying from other causes included older age, higher
tumor stage and the presence of comorbidities, whereas
characteristics associated with dying as a result of breast
cancer included higher tumor-related stage and grade,
ER-negative status and the presence of comorbidities.
The finding that comorbidities had a significant effect
on breast cancer-specific mortality is new and of parti-
cular interest, although relative hazards were signifi-
cantly lower than those for other-cause mortality.
CVD was the leading cause of death in the study
population (15.9%), closely followed by breast cancer
(15.1%). CVD was the primary cause of death for
women of all ages with stage I cancer diagnoses and for
women in the two older age groups with stage II can-
cers. Within each cancer stage group, as women aged,
they were more likely to die as a result of CVD and
“other” causes and less likely to die as a result of breast
cancer, other cancers or COPD. These findings are likely
due to the facts that older women are more likely to
have comorbidities [19] and that women with comorbid-
ities are more likely to die as a result of causes other
than breast cancer. This same age pattern is also seen in
nationwide US vital statistics for the general population
[20]. As expected, our study population was more likely
to die as a result of cancer and less likely to die as a
result of heart disease than older females in the general
study population.
Our study comprised a long follow-up period (median
105 months). Over time, as women survive their breast
cancer, they become less likely to die as a result of their
cancer diagnosis. Still, even within the first five years of
follow-up, CVD remains the leading cause of death for
women of all ages with stage I breast cancers (data not
shown).
Of those women who died as a result of CVD in our
study, only 25.5% were also categorized as having CVD
as a comorbid condition at the time of their breast can-
cer diagnosis. Conversely, of those women who had
CVD as a comorbid condition at the time of their breast
cancer diagnosis and who died during the study period,
41.9% died as a result of CVD. These percentages are
low for several reasons. Most importantly, there was a
long period of follow-up in this study, which allows for
a substantial amount of time for women to develop
CVD subsequent to our detection of the condition at
Figure 1 Proportional distribution of leading causes of death among breast cancer patients ages 66 years and older by age at
diagnosis and by stage of disease from 1 January 1992 through 31 December 2000. CVD: cardiovascular disease.
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has been shown to be associated with long-term cardiac
toxicity in breast cancer patients, particularly in older
patients [21]. In addition, there is likely to be underdiag-
nosis of CVD and/or lack of reporting in the Medicare
record. Underdiagnosis and undertreatment of CVD
may be important issues for women diagnosed with can-
cer, as their cancer diagnosis can be perceived by both
the patient and her caregivers as the overriding medical
priority.
We found four studies that have assessed the effect of
patient characteristics apart from tumor characteristics
on cause-specific breast cancer mortality. Two of these
studies determined that patients over 65 or 70 years of
age were more likely than younger patients to die as a
result of other causes [22,23]. Another study found that
women with three or more comorbid conditions had a
20-fold higher rate of non-breast cancer mortality and a
fourfold higher rate of all-cause mortality than did
women diagnosed with breast cancer without comorbid-
ities [24]. The third study assessed the role of comorbid-
ity in explaining the shorter survival of black breast
cancer patients and found that black women diagnosed
with breast cancer were more likely to die as a result of
causes other than breast cancer [25]. We also found
that black women were slightly more likely to die as a
result of other causes, but, after adjustment for cofac-
tors, we found that black women had survival rates
similar to those of white women.
In the current study, we detected a positive associa-
tion between comorbidities and breast cancer-specific
mortality. We are not aware of a previous study that
has highlighted this relationship. There could be sev-
eral potential explanations for these associations.
Women with comorbidities are less likely to be treated
or may be more likely to experience adverse effects of
therapy and not complete their treatment regimens.
Therefore, women with comorbidities could be more
likely to die as a result of breast cancer. In addition,
there may be misclassification in cause-of-death cod-
ing, and women with metastatic disease may be more
likely to have their cancer listed as the underlying
cause of death when another factor may have been the
true primary cause. A surprising finding in our study
was the significant association between tumor stage
and mortality as a result of other causes. Again, it is
not clear whether these findings indicate that women
with higher-stage tumors are at higher risk of non-can-
cer-related mortality and women with comorbidities
are at higher risk of breast cancer-specific mortality or
whether these findings are due to misclassification in
cause-of-death coding.
Figure 2 Proportional distribution of cumulative leading causes of death by time since breast cancer diagnosis. CVD: cardiovascular
disease.
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the determination of a specific cause of death, so our
study is limited by the validity of death coding. How-
ever, mortality data have been regulated for over 50
years by the World Health Organization’s International
Classification of Diseases [26]. Standard forms and
model procedures are used for the collection of data
and registration of events. One of the goals of this stan-
dardization is to have death certificates that are com-
parable both internationally and nationally. Nonetheless,
the validity of cause-of-death determination is question-
able and has been found to differ across cancer types,
time periods and ages at death [27]. In addition, data
from the Framingham Heart Study [28] have indicated
that heart disease is overestimated as a cause of death
in the general population. If this is true in our study
population, then we cannot conclude that CVD is the
primary cause of death, although the rates of CVD and
breast cancer are likely very similar in this study popu-
lation of older women diagnosed with breast cancer.
The current study is also limited by the fact that Med-
icare data were created for billing purposes and may not
be optimal for clinical research. Recipients of Medicare
may seek care outside their Medicare coverage, such as
long-term care, oral prescriptions of tamoxifen or hor-
monal therapy. Treatments of both breast cancer and
comorbid conditions have improved since the beginning
of the period covered by our study. Information regard-
ing medical history prior to enrolling in Medicare is also
not available. The measurement of comorbidities does
not consider the severity illness or the duration of diag-
nosis, and comorbidities that are present but not cov-
ered by Medicare would result in misclassification of
comorbidity status. In addition, data on possible con-
founding factors, such as smoking, diet and functional
status, are not available in the database.
A sizable portion (34%) of the eligible study partici-
pants were excluded from this study, mainly because
they were enrolled in HMOs, for which Medicare files
are not available. Differences do exist between these two
Medicare healthcare delivery systems. Patients enrolled
in HMOs are generally younger, healthier, diagnosed at
an earlier stage and have better overall survival than FFS
patients [9,29]. There is no reason to believe that the
differences between HMO and FFS patients would bias
the findings observed in our study, but our results are
most generalizable to older adults who are FFS patients.
In addition, there are a number of records with miss-
ing or unknown values for tumor stage and grade as
well as ER status. These missing covariates are related
to the study outcomes. Women who died during the
s t u d yp e r i o dw e r em o r el i k e l yt oh a v eu n k n o w nt u m o r
stage and grade, ER status and surgery status. Missing
tumor characteristics (tumor stage and grade as well as
ER status) do not appear to be related to the specific
cause of death (categorized as “Breast cancer” or “Other
cause”). However, women with unknown surgery status
were more likely to die as a result of breast cancer.
Although the missing data are not random, they are an
intrinsic characteristic of surveillance databases. Ana-
lyses done to account for missing data did not influence
the study findings or conclusions.
Conclusions
Many older women diagnosed with breast cancer die
as a result of comorbid conditions rather than from
breast cancer. Other studies have found that comor-
bidities are associated with increased risk of mortality
from other causes, and in our study we found that
women with comorbidities were more likely to die as a
result of breast cancer as well. We found that after 12
years of follow-up, older women diagnosed with breast
cancer were almost equally likely to die as a result of
breast cancer as they were to die as a result of CVD.
Patient management rightfully focuses on cancer after
diagnosis, but consideration of other existing comorbid
conditions should also be integrated into patient man-
agement and recovery plans [30-32]. Especially among
older breast cancer survivors, risk management of fac-
tors associated with CVD can help improve overall
survival.
Additional material
Additional file 1: Codes used to identify chemotherapy and
radiation treatment in Medicare files. This file contains Medicare
codes that were used to indicate chemotherapy and radiation treatment.
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